trustmebro.to/r/…
✓ checked
trust me, bro:
here is the receipt.
the claim

Adenovirus is a common viral vector used in gene therapy to introduce new genes into specifically targeted cell types.

the verdict
SUPPORTED
the evidence backs this
Recorded sources
6 sources for · 0 against

Counts group repeated records of the same source within each side. They do not measure evidence strength or source independence.

Is it true that Adenovirus is a common viral vector used in gene therapy to introduce new genes into specifically targeted cell types?

Yes. Adenoviruses are widely studied and utilized as viral vectors in gene therapy and virotherapy to deliver genetic payloads and introduce new genes into targeted cell types, particularly in cancer research.

Verdict: SUPPORTED · 6 sources for, 0 against · Last checked

The analysis

The retrieved papers consistently describe adenovirus and engineered adenoviral vectors as established platforms for gene delivery, tumor targeting, and gene therapy applications. The claim is well-supported by multiple recent reviews and experimental studies.

Evidence for · 6
Antigen-directed p53 restoration in <i>TP53</i>-mutated myeloid neoplasms: a hypothesis and theory perspective.
2026
Discusses clinical experience with adenoviral p53 vectors and systemic gene transfer platforms.
Get citation
G, M., S, P., P, B., & A, C. (2026). Antigen-directed p53 restoration in <i>TP53</i>-mutated myeloid neoplasms: a hypothesis and theory perspective.. doi.org. https://doi.org/10.3389/fonc.2026.1874395

See more details
More for · 5
Retargeted adenoviruses for local IgA and CD47 blocker production as a novel cancer therapy.
2026
Highlights retargeted adenoviruses engineered to transform cancer cells into biofactories for targeted delivery.
Get citation
M, C., KP, H., JHM, J., N, B., J, K., D, B., T, K., RHW, P., L, H., D, L., F, W., R, B., M, L., N, G. d. A., M, S., JHW, L., T, V., A, P., & WPR, V. (2026). Retargeted adenoviruses for local IgA and CD47 blocker production as a novel cancer therapy.. doi.org. https://doi.org/10.1038/s44321-026-00477-7

Next-generation oncolytic virotherapy for lung cancer: bridging innovative vector engineering with clinical immunotherapy.
2026
Details oncolytic adenoviruses designed for selective tumor lysis and immunotherapy.
Get citation
J, L., R, Z., G, L., J, W., A, X., & X, H. (2026). Next-generation oncolytic virotherapy for lung cancer: bridging innovative vector engineering with clinical immunotherapy.. doi.org. https://doi.org/10.21037/tlcr-2026-0627

Oncolytic viruses in head and neck cancer: therapeutic promise and translational challenges.
2026
Compares adenovirus and other platforms for selective infection and immunogenic cell death in solid tumors.
Get citation
H, W., H, S., M, Z., Y, M., C, R., Y, S., W, L., C, S., D, L., Y, L., P, Q., & X, S. (2026). Oncolytic viruses in head and neck cancer: therapeutic promise and translational challenges.. doi.org. https://doi.org/10.3389/fimmu.2026.1889008

Recombinant adenoviruses application for cancer vaccines: from genetic design to clinical translation.
2026
Explores adenoviral vectors engineered for enhanced tumor selectivity, replication, and transgene delivery.
Get citation
NA, A., MA, G., MG, A., T, A., AA, A., & AB, M. (2026). Recombinant adenoviruses application for cancer vaccines: from genetic design to clinical translation.. doi.org. https://doi.org/10.3389/fonc.2026.1824087

Bovine Adenovirus 3-Based Viral Vectors for Veterinary Vaccine Development: Progress, Limitations, and Future Directions.
2026
Notes that adenoviral vectors mediate efficient transgene expression and robust immune responses.
Get citation
N, S., T, V., & K, K. (2026). Bovine Adenovirus 3-Based Viral Vectors for Veterinary Vaccine Development: Progress, Limitations, and Future Directions.. doi.org. https://doi.org/10.3390/vetsci13090850

What does the evidence say?

The retrieved papers consistently describe adenovirus and engineered adenoviral vectors as established platforms for gene delivery, tumor targeting, and gene therapy applications. The claim is well-supported by multiple recent reviews and experimental studies.

Receipt History
Anyone with this link can read the claim and its public receipt, including any personal information in that text. Open permanent receipt.
Check your own claim
Challenge the receipt
Requests are recorded for review. This does not start an automatic check or guarantee a response time.

See the evidence timeline

Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.

This receipt is an automated verdict against our published method · not an opinion about any author or publication.
Terms · Privacy · How verdicts work